BioSpace News Archive

TransformativeMed, the leader in transforming electronic health records (EHRs) with apps directly embedded within the EHR, today announced a partnership with Beebe Healthcare (Beebe) in Delaware to improve the health system’s clinical workflow efficiency, patient care communication and overall clinician experience with their electronic health record (EHR) system.

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the following healthcare conferences:

Synthorx, Inc., a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced the Company will present at multiple upcoming investor conferences

CENTOGENE announced a new data access and collaboration agreement with Pfizer Inc.

BrainStorm Cell Therapeutics Inc. announced that the Japan Patent Office has issued a Decision to Grant a Patent for BrainStorm’s Patent Application, number: 2016-548691, titled: ‘Method of Qualifying Cells.’

Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type

Cassiopea SpA announced that it has received approval from the German Authority BfArM and the coordinating ethical committee and will now proceed to enroll the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia in females.

Astrotech Corporation reported its financial results for the first quarter of fiscal year 2020, which ended September 30, 2019.

Eligible patients in Wales will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, announced that management will present a company overview at the following investor conferences